The mitotic spindle checkpoint plays a crucial role in regulating accurate chromosome segregation and preventing
Introduction
Spindle damage induces prolonged arrest of cellular mitosis, but the cells eventually enter the G 1 phase despite failed chromosome segregation and/or cytokinesis. Under normal conditions, these cells undergo a second, p53-dependent cell cycle arrest, and eventually succumb to apoptotic cell death (1) (2) (3) (4) . However, p53-deficient cells do not undergo this second arrest and eventually adapt and become profoundly polyploid (and eventually aneuploid) in a manner similar to that observed in cells deficient for mitotic checkpoint proteins (2, (5) (6) (7) (8) . Recent studies have shown that treatment with microtubule inhibitors induces p53 protein expression only after tetraploid cells exit mitotic arrest and progress to interphase (9) . Notably, chromosome nondisjunction results in tetraploidization via mitotic failure (10) and p53 has an intrinsic ability to eliminate tetraploid cells (11) that may otherwise proceed to aneuploidy (12) . These findings strongly suggest that p53 acts at some point in the postmitotic cell cycle, particularly in cases of mitotic defect. Other studies have shown that microtubule disruption induces prolonged mitotic arrest in association with phosphorylation-induced stabilization of the p53 protein (13) . Thus, the induction and/or activation of p53 by mitotic checkpoint activation seems to be essential for protecting cells against the abnormal chromosomal ploidization induced by mitotic defects. Furthermore, these previous findings suggest the existence of functional cross-talk between the mitotic checkpoint and p53-dependent postmitotic controls. Nevertheless, the molecular mechanisms governing p53 activation following prolonged, checkpoint-activated mitotic arrest have not yet been fully elucidated.
During mitotic checkpoint activation, BubR1 and other checkpoint components form an inhibitory ternary complex with an E3 ubiquitin ligase called the anaphase-promoting complex, and its substrate-specific activator, Cdc20. BubR1 monitors the proper attachment of microtubules to kinetochores, and links the regulation of chromosome-spindle attachment to mitotic checkpoint signaling (14) (15) (16) . Several studies have shown that disruption of BubR1 activity results in a loss of checkpoint control, chromosomal instability (caused by premature anaphase), and/or early onset of malignancy (14, (17) (18) (19) . We previously showed that BubR1 functions as a potent apoptotic molecule for preventing the adaptation of abnormal, chromosomally unstable mitotic cells (20) . Collectively, these observations suggest that BubR1 forms a functional link between prolonged mitotic checkpoint activation and subsequent postmitotic adaptation.
Materials and Methods
Plasmid construction and generation of recombinant adenovirus. The full-length cDNA sequence of the human BubR1 gene has been previously described (14) . The cDNA fragments of the BubR1 gene were PCR-amplified and inserted into the pCMV-HA vector to generate pCMV-HA-BubR1 wild-type (WT), 1 to 525 and 526 to 1050. The cDNAs for BubR1 WT, 1 to 525 and 526 to 1050, and two mutant versions of BubR1, K795R and F1022S, were subcloned into the Myc epitope-encoding pcDNA3.1 vector to generate pcDNA-MycBubR1 WT, 1 to 525, 526 to 1050, K795R, and F1022S. Glutathione S-transferase (GST) fusion constructs for expression in Escherichia coli were generated by inframe insertion of PCR fragments encoding BubR1 amino acid residues 1 to 300, 1 to 525, 401 to 700, and 526 to 1050 into the pGEX-KG vector (Pharmacia). The p53 deletion mutant was constructed by in-frame insertion of restriction fragments encoding p53 amino acids 1 to 144 or 143 to 393 into the pGEX-KG vector. The human BubR1 small interfering RNA (siRNA) expression plasmids were created by inserting two sets of siRNA oligonucleotides (5 ¶-gatccccaagggttcagagccatcagttcaagagactgatggctctgaaccctttttttggaaa-3 ¶/ 5 ¶agcttttccaaaaaaagggttcagagccatcagtctcttgaactgatggctctgaacccttggg-3 ¶ and 5 ¶-gatccccggagatcctctacaaagggttcaagagaccctttgtagaggatctcctttttggaaa-3 ¶/5 ¶-agcttttccaaaaaggagatcctctacaaagggtctcttgaaccctttgtagaggatctccggg-3 ¶, with the BubR1-targeting region underlined) into the pSuper.Retro.puro and pSuper.puro vectors (Oligoengine), generating the pSuper.Retro.puro-BubR1 siRNA and pSuper-BubR1 siRNA plasmids, respectively. The recombinant adenovirus expressing wild-type BubR1 has been previously described (20) .
Cell KD cell lines were generated by transfecting the HCT116 and HCT116-p53 KO cells with either pSuper-BubR1 siRNA or the empty pSuper.Retro.puro vector. Colonies showing resistance to puromycin (10 Ag/mL) were clonally isolated, and immunoblotting and immunofluorescence assays with an anti-BubR1 antibody (BD Biosciences PharMingen) were used to screen for the suppression of BubR1 expression.
In vitro binding assays and immunoprecipitation. For the GST pulldown assays, the fusion proteins were adsorbed onto glutathione-protein A/G-Sepharose beads (Amersham Biosciences) and incubated with wholecell extracts (4 mg) from asynchronized or nocodazole-treated HeLa or HCT116 cells. The bound proteins were analyzed by SDS-PAGE, and either p53 or BubR1 were detected by immunoblotting with the corresponding antibody. The in vitro-translated BubR1 protein was produced using a TNTcoupled transcription/translation kit (Promega). For immunoprecipitation, asynchronized or nocodazole-treated HeLa cells were lysed in an immunoprecipitation buffer [50 mmol/L Tris-HCl (pH 7.5), 150 mmol/L NaCl, 1% NP40, 1 mmol/L EDTA, 1 mmol/L phenylmethylsulfonyl fluoride (PMSF), and 1 mmol/L DTT] containing a protease inhibitor cocktail (Sigma). Each cell extract was incubated with antibodies against BubR1 or p53, or normal IgG (control) for 2 h at 4jC, followed by incubation with protein A/G-Sepharose beads for an additional 2 h. The beads were pelleted, washed four times with immunoprecipitation buffer, and analyzed by immunoblotting.
In vitro kinase assays. The cell lysates were incubated with either monoclonal anti-BubR1 antibody or normal mouse IgG, followed by an additional incubation with protein A/G-Sepharose beads. The beads were washed twice with a kinase buffer [100 mmol/L Tris-HCl (pH 7. Synchronization and cell cycle analysis. Synchronized populations were generated by treating the control HCT116 and HCT116-BubR1 KD cells with nocodazole (200 ng/mL) for 12 h, and then releasing them into normal culture medium in the presence or absence of cycloheximide (50 Ag/mL). The cells were harvested at various times after synchronization, and processed for immunoblotting analysis. For flow cytometric analyses, control HCT116 and HCT116-BubR1 KD cells were treated with 300 ng/mL of nocodazole, harvested at various times posttreatment, and then fixed and stained with propidium iodide for flow cytometric analysis. The DNA contents of 10,000 cells per sample were analyzed on a Becton Dickinson FACScan cytometer using the CellQuest and WinMDI2.8 software packages.
Immunoblotting analysis and immunofluorescence. For immunoblot analysis, the cells were synchronized as described above or left (IVT-BubR1 ) was incubated with beads binding either GST or GST-p53 (fulllength). After binding, beads were resolved by SDS-PAGE and analyzed by immunoblotting using anti-BubR1 antibody (lanes 1-3 ) . Purified His-p53 protein was incubated with beads binding GST-BubR1 (full-length). The beads were resolved by SDS-PAGE and analyzed by immunoblotting using anti-p53 antibody (lanes 4-6 ) , Ser 46 , and Ser 392 (Cell Signaling Technology), or anti-HA (Roche) antibodies. For immunofluorescence, the cells were cultured on 18-mm coverslips and fixed in 5% formaldehyde for 10 min. The fixed cells were washed, permeabilized in PBS containing 0.1% Triton X-100, and incubated with the appropriate primary antibody at room temperature for 2 h. The cells were then washed and further incubated for 1 h with goat anti-mouse IgG conjugated with either FITC or Cy5. The cells were washed, stained with Hoechst dye for visualization of DNA, and viewed under a confocal microscope (Zeiss 510 Meta).
Live cell imaging. To estimate the duration of mitosis, cells were transfected with an expression plasmid encoding H2B-GFP for visualization of chromosomes, and then imaged in DT 0.15 mm dishes in McCoy's supplemented medium containing 10% FBS. Every 2 min for 2 h, 0.5-s exposures were acquired using a 20Â NA0.75 objective on an LSM500 META confocal microscope (Carl Zeiss).
Results
BubR1 interacts with p53 in vitro and in vivo. To elucidate how BubR1 monitors mitotic and/or postmitotic cell cycle regulation, we used a complex proteomics approach to screen for novel BubR1-interacting proteins. Briefly, we extracted total cellular proteins from HeLa cells, immunoprecipitated these proteins with anti-BubR1 antibody, and analyzed the resulting immunocomplexes by two-dimensional gel electrophoresis followed by mass spectrometry (data not shown). Subsequent matrix-assisted laser desorption ionization-time of flight analysis led to the identification of several BubR1-interacting molecules, including p53.
To begin assessing the importance of this putative p53-BubR1 interaction, we first confirmed its existence by generating a fulllength p53/GST fusion protein, and then used immunoblotting to detect the p53-BubR1 interaction in the in vitro-translated extract (Fig. 1A, lanes 1-3) . Pull-down assays revealed that GST-p53 did in fact bind to BubR1. Similarly, we generated a full-length BubR1/GST fusion protein and examined the interaction between GST-BubR1 and purified His-p53 (Fig. 1A , lanes 4-6), which again revealed that BubR1 and p53 were present in the complex formed in vitro. Consistent with these findings, immunoprecipitation with antiBubR1 antibody and subsequent immunoblotting with an anti-p53 antibody (or the reverse experiment) showed that BubR1 and p53 form a complex in vivo (Fig. 1B) . To define the domains responsible for this BubR1-p53 interaction, we incubated a series of GST-BubR1 and GST-p53 deletion mutants with extracts from HeLa cells expressing wild-type BubR1 or p53. As shown in Fig. 1C , a fragment consisting of the BubR1 NH 2 -terminal homology domain (amino acids 1-300), which is required for the kinetochore localization of BubR1, formed a complex with p53, whereas the central and COOHterminal regions of BubR1 did not. Similarly, a fragment containing the NH 2 -terminal end of p53 (amino acids 1-143), which is required for transcriptional activity and MDM2 binding, interacted with BubR1, whereas amino acids 144 to 393 of p53, containing the DNAbinding and oligomerization motifs, did not (Fig. 1D) . In a positive control experiment, we confirmed that BubR1 and p53 interacted with their well-defined binding partners, Bub3 and MDM2, respectively, under these experimental conditions ( Fig. 1C and D) .
To determine whether the BubR1-p53 interaction was regulated in a cell cycle-dependent manner, we treated asynchronized HeLa cells with the microtubule-inhibiting agent nocodazole for 14 h (to generate synchronized cells), and then released cells into the cell cycle for 2 h (to generate postreleased cells). As shown in Fig. 2A , flow cytometry analysis revealed that a larger proportion of treated cells were in the M phase, and that the phosphorylations of both BubR1 and histone H3, as mitotic markers, were rapidly elevated in these cells (Fig. 2B) ; moreover, this response has been shown to be required for checkpoint control (14, 15) . Next, we assessed the relationship between the cell cycle and the BubR1-p53 interaction by incubating GST-p53(1-143) or GST-p53(144-393) with endogenous BubR1, and found that the interaction between GST-p53(1-143) and BubR1 was significantly higher in synchronized cells than in asynchronized or postreleased cells (Fig. 2C) . To confirm this result, we immunoprecipitated endogenous p53 from Figure 2 . BubR1-p53 interaction may occur in a cell cycle-dependent manner. A and B, HeLa cells were treated with nocodazole (Noco ; 100 ng/mL) for 14 h and then released into the cell cycle for 2 h (Noco/Release). Cells were harvested, stained with propidium iodide, and analyzed by flow cytometry to determine their DNA contents. Asyn, asynchronized cells (A ). Lysates from asynchronized or synchronized HeLa cells were analyzed by immunoblotting using anti-BubR1, anti-phospho-H3 (P-H3 ), or anti-actin antibody (B). C, lysates were prepared as described in (A) and (B ), incubated with GST, GST-p53(1-143), or GST-p53(144-393), and bound BubR1 was detected by immunoblotting. D, HeLa cell lysates (4 mg) were immunoprecipitated with normal IgG or anti-p53 antibody. Immunoprecipitates were immunoblotted with anti-BubR1 or anti-p53 antibody (control). Arrowheads, hyperphosphorylated (top ) and hypophosphorylated (bottom ) forms of BubR1 polypeptides.
asynchronized, synchronized, and postreleased cell lysates using anti-p53 antibody, and immunoblotted the immunocomplexes obtained with anti-BubR1 antibody. Consistent with the above results, we observed an increased interaction between BubR1 and p53 in synchronized cells (Fig. 2D ), indicating that this interaction occurs in a mitotic cell cycle-dependent manner, with high levels of interaction in cells arrested in mitosis and relatively low levels in cells that had exited mitosis arrest. ATP. GST-p53 was resolved and visualized as described above (lanes 5-7, top ). *, nonspecific bands. HA-tagged BubR1 proteins were detected with an anti-HA antibody (lanes 5-7, bottom ). C, nocodazole-treated HeLa cells were lysed and immunoprecipitated with anti-BubR1 or anti-IgG (control) antibodies, and the resulting immunoprecipitates were incubated with either purified GST or GST-p53 in the presence of unlabeled ATP. Bound p53 proteins were resolved by SDS-PAGE and detected using antibodies against p53 phosphorylated at specific residues (Ser 15 , Ser 20 , and Ser 15 ). GST proteins were resolved by SDS-PAGE and visualized by Ponceau staining (bottom ). Arrowhead, degraded form of the p53 polypeptide. D, HeLa cells were treated as follows: synchronized by double thymidine block and released for 2 h (Thy-DB ), nocodazole treatment for 14 h (NR0 ), and nocodazole treatment and postrelease into the cell cycle for 3 h (NR3), 5 h (NR5 ), or 6 h (NR6 ). Cell lysates were immunoprecipitated with an anti-BubR1 antibody or normal IgG, and the resulting immunocomplexes were incubated with GST-p53 fusion proteins in the presence of [g 32 P]ATP (lanes 1-12 ) . HeLa cells were transfected with the Myc-BubR1WT, Myc-BubR1(1-525), Myc-BubR1(526-1050), Myc-BubR1K795R, or Myc-BubR1F1022S expression plasmids. Immunoprecipitation and phosphorylation analyses were done as described above. *, phosphorylated GST-p53 proteins. Myc-tagged BubR1 proteins were detected with an anti-Myc antibody (lanes 13-18, bottom ).
BubR1 kinase contributes to phosphorylation of p53. To examine whether the BubR1-p53 interaction leads to p53 phosphorylation, protein lysates from control and nocodazole-treated HeLa cells were immunoblotted with antibodies specific for p53 phosphorylated at residues Ser 9 , and Ser 392 were unaltered ( Fig. 3A; Supplemental Fig. S1 ). Consistent with previous reports (8, 13, 21) , our results suggest that p53 is phosphorylated and activated in response to late-stage mitotic spindle damage. Therefore, to determine whether the observed increase in phosphop53 was due to BubR1 activity, we did in vitro BubR1 kinase assays using GST-p53 as a substrate. Immunoprecipitation of BubR1 from HeLa cells followed by incubation with [g 32 P]ATP and GST-p53 or GST alone revealed that the BubR1 immunocomplexes clearly 19-36 ) . D, HCT116 cells were transfected with the control pSuper (pS) or pSuper-BubR1 siRNA (pS-BubR1 siRNA) vectors and cultured for 18 h. Transfected cells were infected with rAd-LacZ or rAd-BubR1 at 2 Â 10 6 plaque-forming units/mL, as described previously (20) . After incubation for an additional 36 h, the cells were harvested and processed for immunoblotting with anti-BubR1, anti-p53 (DO-1 ), and anti-actin antibodies.
phosphorylated GST-p53 but not GST alone (Fig. 3B, lanes 3 and 4) . Similarly, when lysates from nocodazole-treated HCT116 cells expressing HA-tagged wild-type BubR1 (HA-BubR1WT), HABubR1(1-525), or HA-BubR1(526-1050) were immunoprecipitated with an anti-HA antibody and further incubated with GST-p53, immunoprecipitated BubR1WT phosphorylated GST-p53, whereas BubR1(1-525) and BubR1(526-1050) did not (Fig. 3B, lanes 5-7, top) .
Next, we examined whether the spindle damage-induced phosphorylations of p53 at Ser 15 and Ser 46 were mediated by BubR1. In nocodazole-treated HeLa cell extracts subjected to immunoprecipitation with anti-BubR1 antibodies or normal IgG (control) followed by incubation of the immunocomplexes with GST-p53 or GST alone and unlabeled ATP, the BubR1 immunocomplexes showed a strong signal with antibodies against p53 phosphorylated at Ser 15 and Ser 46 , but not Ser 20 ( Fig. 3C ), indicating that BubR1 was capable of phosphorylating p53 in vitro. Furthermore, we compared the phosphorylation of p53 by BubR1 at different stages of the cell cycle. HeLa cells synchronized by either thymidine-double block/postrelease (Thy-DB, G 2 phase), nocodazole treatment (NR0, M phase) or nocodazole treatment/postrelease (NR5, exit of mitosis) were immunoprecipitated with anti-BubR1 antibodies or preimmune IgG (negative control). The resulting BubR1 immunocomplexes were incubated with [g 32 P]ATP and purified GST-p53 fusion proteins (Fig. 3D, lanes 1-6) . Phosphorylation of the GST-p53 proteins by the BubR1 immunocomplexes was detected in samples from all three types of cell lysates, with higher levels clearly present in lysates prepared from nocodazole-treated cells (Fig. 3D, compare lanes 4  and 5 and lane 6) . Furthermore, phosphorylation analysis using BubR1 immunoprecipitated from nocodazole-synchronized and postrelease cells at different time intervals revealed that the levels of radiolabeled GST-p53 protein gradually decreased as cells advanced from mitotic arrest to interphase (Fig. 3D , compare lanes 10 and 11 and lane 12 ), indicating that increased phosphorylation of p53 by BubR1 is likely to be a consequence of the increased interaction of p53 and BubR1 during mitosis. To further show that the phosphorylation of p53 requires active BubR1, we introduced point substitutions in the lysine and phenylalanine residues in the catalytic kinase domain of BubR1 potentially essential for phosphorylation reactions (K795R and F1022S, respectively), and expressed these mutants from a Myctagged mammalian expression construct. The mutant BubR1 proteins showed significantly reduced autophosphorylation and kinase activities (refs. 14, 20; data not shown). We then transfected cells with the K795R, F1022S, or wild-type Myc-tagged BubR1 constructs, along with constructs encoding amino acids 1 to 525 and 526 to 1050 as negative controls (Fig. 3D, lanes 13-18) . Importantly, the K795R and F1022S point substitutions in BubR1 significantly reduced the phosphorylation of p53 compared with that by BubR1WT, strongly suggesting that the activity of BubR1 kinase is important for the phosphorylation of p53.
BubR1 regulates the stability of p53 via phosphorylation. We tested the effect of BubR1 on the stability and activity of p53 by transfecting HeLa cells with siRNA against BubR1 or luciferase (negative control). Interestingly, cells transfected with the BubR1 siRNA (which substantially depleted BubR1 protein levels) contained markedly lower levels of p53 (Fig. 4A) . Next, we generated stable BubR1 knock-down (BubR1 KD ) cells by transfecting HCT116 Research.
on April 14, 2017 . © 2007 American Association for Cancer cancerres.aacrjournals.org Downloaded from cells with siRNA against BubR1. The expression of BubR1 in these cells was f70% lower than that in control cells (Fig. 4B) . We then compared p53 levels between HCT116 parental and HCT116-BubR1 KD cells by treating cells with nocodazole for 12 h (which induced p53 phosphorylation) and then releasing them into the cell cycle (Fig. 4C, lanes 1-18) . At the indicated time points, cells were harvested and immunoblotted with antibodies specific for p53 phosphorylated at Ser 9 (negative control), Ser 15 , and Ser 46 . Interestingly, whereas phosphorylation was markedly evident at residues Ser 15 and Ser 46 in the parental HCT116 cells, the corresponding levels were very low in HCT116-BubR1 KD cells (Fig. 4C, lanes 1-18) . To further examine the stability of p53, we released HCT116 parental and HCT116-BubR1 KD cells from nocodazole, exposed the cells to the protein translation inhibitor, cycloheximide, and then monitored the levels of p53 phosphorylation over time by immunoblotting and subsequent image analysis (Fig. 4C, lanes 19-36) . Exposure to cycloheximide for 60 min decreased the levels of p53 phosphorylation at residues Ser 15 and Ser 46 by almost 80% in HCT116-BubR1 KD cells, whereas steady state levels were observed in parental cells. Moreover, the level of phosphorylation at p53 residue Ser 15 in HCT116-BubR1 KD cells at 60 min posttreatment was similar to that in parental HCT116 cells at 180 min posttreatment. At 120 min posttreatment, HCT116-BubR1 KD cells showed almost no detectable phosphorylation at residues Ser 15 and Ser 46 , whereas both phospho-p53 proteins were stably detected in parental cells. These results were confirmed by examining two additional independent BubR1 KD clones (data not shown). Together, these data strongly suggest that BubR1 regulates the stability of p53 via phosphorylation. Finally, to investigate whether p53 destabilization by targeted inhibition of BubR1 expression could be compromised by the introduction of exogenous BubR1 protein, we transfected HCT116 cells with control pSuper or the pSuper-BubR1 siRNA plasmid and further infected the cells with a recombinant adenovirus expressing LacZ (rAd-LacZ; control) or wild-type BubR1 (rAd-BubR1; Fig. 4D ). We found that infection of rAd-BubR1 significantly restored p53 levels in BubR1 siRNA-transfected HCT116 cells, whereas infection with the control rAd-LacZ did not. In addition, immunofluorescence analyses at the single cell level confirmed that significantly less p53 was present in BubR1 knock-down cells compared with BubR1-competent parental cells (Supplemental Fig. S2 ). To rule out the possibility that the reduced levels of BubR1 expression in the knock-down cells was unrelated to BubR1-mediated checkpoint signaling, we treated HCT116 parental and HCT116-BubR1 KD cells with nocodazole, and harvested the cells at various time points for flow cytometry (Fig. 5A) . Consistent with previous reports (14, 20) , the frequency of aneuploid/polyploid cells was dramatically higher in BubR1 KD cells than in BubR1-competent control cells, indicating that the levels of BubR1 protein in the knock-down cells seemed to correlate with decreased BubR1-mediated mitotic checkpoint function. Taken together, these data strongly suggest that BubR1 regulates the protein stability of p53.
Inhibition of BubR1 expression accelerates chromosomal instability and polyploidy in p53-null cells. It is generally believed that a partial loss of checkpoint function was not inherently lethal, and that chromosome missegregation during mitosis causes chromosome damage and other mitotic defects. Thus, as our established BubR1 knock-down cells showed f70% BubR1 expression compared with parental cells, they could be considered to reflect a partial inactivation of the mitotic checkpoint. It is also believed that more than half of the human cancers show alterations in the expression and/or sequence of the p53 gene. Therefore, to investigate the effect of BubR1 depletion on the frequency of polyploidy in p53-null cells, we developed BubR1/p53 double knock-down/knock-out cells (HCT116-p53 KO / BubR1 KD ), using our BubR1 KD cells and p53-null cells (HCT116-p53 KO ). Initially, we synchronized HCT116, HCT116-p53 KO , and HCT116-BubR1 KD cells using nocodazole and then subjected them to flow cytometric analysis. Consistent with previous reports (1, 3-7) , HCT116-p53 KO cells subjected to mitotic spindle damage showed increased polyploid cell populations (8N) and decreased apoptotic cell death, whereas parental cells avoided polyploidy by exiting mitotic arrest and undergoing apoptosis (Fig. 5A ). These phenotypes are very similar to those seen in HCT116-BubR1 KD cells (Fig. 5A) . Next, HCT116, HCT116-p53 KO , HCT116-BubR1 KD , and HCT116-p53 KO /BubR1 KD cells were exposed to a reduced concentration of nocodazole that was sufficient to arrest cells in mitosis but was insufficient to induce widespread polyploidy or apoptosis (Fig. 5B) . Our results revealed that nocodazole-treated parental cells accumulated primarily in the mitotic phase (4N), with relatively small proportions of apoptotic and polyploid cells observed in these samples. Under the conditions used, HCT116-p53 KO and HCT116-BubR1 KD cells also accumulated in the mitotic phase; apoptosis was significantly less prevalent in p53-null cells compared with parental cells, whereas polyploidy was slightly but significantly more prevalent in BubR1-depleted cells compared with parental cells. Interestingly, HCT116-p53 KO /BubR1 KD cells showed a dramatic reduction in the mitotic cell population and a marked increase in the polyploid cell population relative to HCT116-p53 KO and HCT116-BubR1 KD cells. Moreover, the prevalence of polyploidy in HCT116-p53 KO /BubR1 KD cells (f60%) was much higher than that seen in HCT116-p53 KO (f5%) or HCT116-BubR1 KD (f20%) cells after 60 to 72 h of nocodazole treatment. Thus, under conditions of prolonged mitotic arrest due to treatment with a microtubule inhibitor, coinhibition of BubR1 and p53 induced marked chromosomal instability and polyploidy.
To examine the effect of BubR1 and p53 knock-down/knock-out on the normal timing of mitotic progression, HCT116, HCT116-p53 KO , HCT116-BubR1 KD , and HCT116-p53 KO /BubR1 KD cells were synchronized at the boundary between the G 1 and S phases, using a double thymidine block. Following release from the G 1 or S phases in the absence of microtubule inhibitors, cells were harvested at various time points and analyzed by flow cytometry. As shown in Fig. 6A , in the presence of a functional spindle, cells depleted of both BubR1 and p53 (HCT116-p53 KO /BubR1 KD ) did not differ significantly from p53-null cells (HCT116-p53 KO ) in terms of progression through the S and G 2 phases, mitosis, or exit from mitosis. Next, we examined the effect of BubR1 and/or p53 inhibition on mitotic cell cycle progression at the single cell level, using time-lapse photomicroscopy of HCT116, HCT116-p53 KO , HCT116-BubR1 KD , and HCT116-p53 KO /BubR1 KD cells transfected with an expression plasmid encoding an H2B-GFP fusion protein for the visualization of chromosomes. As each cell entered mitosis, nuclear envelop breakdown was set as time zero, and the relative times for the individual cell types to complete chromosome separation were determined ( Fig. 6B and C) . In HCT116-p53 KO cells, the time to completion of chromosome separation was 54.4 (F6.3) min, which was very similar to that of control HCT116 cells, 53.7 (F7.9) min. In contrast, HCT116-BubR1 KD cells showed a significantly faster exit from the mitotic cell cycle, at 41.5 (F4.6) min. However, further inhibition of BubR1 in p53-null cells (HCT116-p53 KO /BubR1 KD ) did not seem to additionally retard or accelerate the duration of mitosis in the presence of a functional spindle. In summary, our results indicate that BubR1 interacts with, phosphorylates, and stabilizes p53, and further provide evidence that p53 activation induced by mitotic spindle damage is a response to BubR1-mediated signaling.
Discussion
Normal cells harboring competent BubR1 and p53 proteins undergo prolonged mitosis arrest in response to spindle damage, and then subsequently exit mitosis and undergo apoptosis. Defects in BubR1 not only augment the development of aneuploidy, but also compromise spindle damage-induced apoptotic cell death. Similarly, p53-deficient cells do not undergo apoptosis, instead proceeding to aneuploidy. Although a recent study showed that prolonged mitotic arrest triggered by microtubule disruption could stabilize p53 by phosphorylation, in a pattern distinct from that seen in response to DNA damage (13), the molecular mechanisms underlying this effect are unknown. Additionally, although it is known that numerous kinases regulate the phosphorylation of p53, and the phosphorylation status of p53 is known to affect its stability, sequence-specific DNA binding and protein interaction affinity with target proteins, the mechanism by which these kinases trigger phosphorylation of p53 during mitosis are unknown. In this work, we found that the BubR1 mitotic checkpoint kinase interacts with p53 and contributes to p53 stabilization via phosphorylation. Silencing of BubR1 expression reduces this phosphorylation and consequently decreases the stability of p53, and this effect can be recovered by the introduction of exogenous BubR1 protein. These results collectively indicate that the p53 response to mitotic spindle damage is probably dependent on BubR1-mediated signaling, and that a functional cross-talk exists between BubR1 and p53 at the potential level of postmitotic regulation.
BubR1 protein and phosphorylation levels are higher in cells subjected to mitotic spindle damage compared with cells undergoing normal mitotic progression (14) . Because BubR1 in unattached kinetochores exhibits a higher degree of phosphorylation than its soluble counterpart (22), we hypothesized that BubR1 hyperphosphorylation might contribute to stabilizing and/or activating p53 via phosphorylation. Interestingly, two kinaseinsufficient mutants of BubR1 (BubR1K795R and F1022S) yielded significantly reduced levels of p53 phosphorylation. Moreover, BubR1-mediated phosphorylation of p53 was also reduced in cells exiting from mitosis following recovery from spindle damage. These observations strongly support our notion that the induction of p53 following mitotic checkpoint activation requires signaling via BubR1-mediated phosphorylation. Furthermore, the functional cross-talk between BubR1 and p53 is likely to be an important factor in the determination of subsequent postmitotic consequences, such as adaptation or apoptosis.
Two mitotic kinases, Aurora-A and polo-like kinase 1 (Plk1), regulate the mitotic cell cycle by controlling chromosome segregation, spindle assembly, and commitment to mitosis (23, 24) . Aurora-A and Plk1 physically bind to and phosphorylate p53 (25, 26) . Interestingly, whereas mitotic spindle damage induces phosphorylation and activation of p53, the phosphorylation events induced by Aurora-A and Plk1 actually reduce the activity of p53. Moreover, because Aurora-A and Plk1 are overexpressed in many human cancer cells (27) (28) (29) , whereas BubR1 tends to be downregulated in cancer cells (20) , it is possible that BubR1 antagonizes the inhibitory effects of Aurora-A or Plk1 on p53. Although it is likely that p53 is also phosphorylated and activated by additional kinases that are induced by mitotic spindle damage, our present results suggest that p53 activation in response to mitotic spindle damage requires signaling via BubR1-mediated phosphorylation.
Because p53 degradation predominantly involves MDM2-mediated ubiquitination (30), we tested whether the stability of p53 was regulated by a mitotic spindle damage-induced functional interaction between BubR1 and MDM2. We transfected HeLa cells with siRNA targeting BubR1 and examined the levels of MDM2. In contrast to the dramatic p53 decrease observed after BubR1 siRNA knock-down, we did not observe any significant change in the MDM2 levels of these cells (Supplemental Fig. S3A) . Furthermore, no significant interaction between BubR1 and MDM2 was detected in mammalian two-hybrid (Supplemental Fig. S3B ) and immunoprecipitation (data not shown) experiments under conditions that yielded reproducible interactions between these two proteins in our experimental system. These results indicate that the destabilization of p53 observed in BubR1-depleted cells was independent of the MDM2-mediated ubiquitination pathway (Supplemental Fig. S3 and S4 ). However, in interphase cells, BubR1 could theoretically stabilize p53 by outcompeting its negative regulator, MDM2, because the BubR1-binding domain of p53 overlaps with the MDM2-binding domain (Fig. 1D ). In addition, it is theoretically possible that BubR1 might transcriptionally and/or translationally regulate p53 expression. Importantly, this study showed that total p53 and p53 phosphorylated at Ser 15 and Ser 46 all accumulated to high levels in parental cells following mitotic spindle damage (Fig. 4C) , and then gradually decreased as the cells progressed through the cell cycle to interphase. In addition, our kinase analyses revealed that kinase-insufficient BubR1 mutants were associated with significantly reduced phosphorylation of p53 (Fig. 2D) , and BubR1-mediated phosphorylation of p53 was reduced in interphase cells or cells exiting from mitosis following spindle damage (Fig. 2D) . Together, these findings strongly suggest that the effects of BubR1 on p53 exogenously expressed in mitotic cells was likely due to posttranslational modification of p53 rather than transcriptional control in the transcriptionally inactive mitotic cells.
Our additional investigation into the effect of BubR1 depletion on the frequency of polyploidy in p53-null cells in response to spindle damage revealed that cells depleted of both BubR1 and p53 showed significantly more aneuploidy/polyploidy than p53-null cells and BubR1-depleted cells (Fig. 5A and B) . However, in the presence of a functional spindle, cells depleted of both BubR1 and p53 showed no significant differences from p53-null cells in terms of progression through the S and G 2 phases, mitosis, or exit from mitosis (Fig. 5) . These findings imply that BubR1 knockdown in p53-null cells augments the chromosomal instability and polyploidy induced by spindle damage. We recently reported that the sustained inactivation and/or down-regulation of BubR1 prevented the induction of apoptosis that normally follows postmitotic adaptation (20) . Therefore, the findings of the present study provide evidence that p53 induction by mitotic checkpoint activation is a component of the BubR1-mediated checkpoint signaling pathway.
Taken together, our results strongly suggest that BubR1 interacts with and phosphorylates p53, thus contributing to the stabilization of p53. This functional cross-talk between BubR1 and p53 may represent a new molecular insight into how p53 is activated in response to spindle damage.
